<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have previously reported presentation serum <z:chebi fb="19" ids="27568">selenium</z:chebi> level to be predictive of outcome in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This has now been studied in a further 430 patients, 163 with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 156 with Hodgkin <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>), and 111 with Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="2" pm="."><plain>Serum <z:chebi fb="19" ids="27568">selenium</z:chebi> was below the UK <z:mpath ids='MPATH_458'>normal</z:mpath> reference range in 45% of patients, and correlated with serum albumin (r=0·24-0·46, P&lt;0·001-0·003) in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types </plain></SENT>
<SENT sid="3" pm="."><plain>Independent predictors of presentation <z:chebi fb="19" ids="27568">selenium</z:chebi> were; French-American-British subtype and albumin (P&lt;0·001 for both) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (P=0·002) and B-symptoms (P=0·01) in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, and albumin (P&lt;0·001) in FL </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, response to first line therapy was lower in patients with low serum <z:chebi fb="19" ids="27568">selenium</z:chebi>, but <z:chebi fb="19" ids="27568">selenium</z:chebi> was no longer predictive of response when other variables were entered into a multivariate model </plain></SENT>
<SENT sid="5" pm="."><plain>Low <z:chebi fb="19" ids="27568">selenium</z:chebi> was also associated with a worse overall survival in FL [Hazard Ratio (HR) 2·3, 95% confidence interval (CI) 1·4, 4·0] and a trend to a worse overall survival in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (HR 1·43, 95% CI 0·96, 2·13) by univariate Cox regression analysis, but not by multivariate analysis </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, low serum <z:chebi fb="19" ids="27568">selenium</z:chebi> is associated with a worse outcome in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, but is not independently predictive, suggesting that it reflects other factors </plain></SENT>
</text></document>